David G S Perahia

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
    David G S Perahia
    Lilly Research Centre, Windlesham, Surrey, UK
    Int Clin Psychopharmacol 21:311-7. 2006
  2. doi request reprint Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER
    Catherine Reed
    Eli Lilly and Company Ltd, Erl Wood Manor, Windlesham, Surrey, UK
    J Affect Disord 113:296-302. 2009
  3. doi request reprint Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression
    David G S Perahia
    Lilly Research Centre, EMC Building, Erl Wood Manor, Sunninghill Road, Windlesham GU20 6PH, Surrey, UK
    J Psychiatr Res 43:512-8. 2009
  4. ncbi request reprint A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder
    David G S Perahia
    Lilly Research Centre, Erl Wood, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
    J Psychiatr Res 42:22-34. 2008
  5. ncbi request reprint Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial
    David G S Perahia
    Lilly Research Centre, Erl Wood, Windlesham, Surrey, UK
    J Clin Psychiatry 70:706-16. 2009
  6. ncbi request reprint Factors influencing depression endpoints research (FINDER): study design and population characteristics
    Ana Garcia-Cebrian
    Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
    Eur Psychiatry 23:57-65. 2008
  7. ncbi request reprint A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression
    David G S Perahia
    Lilly Research Centre, Windlesham, UK
    J Affect Disord 108:33-41. 2008
  8. ncbi request reprint Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques
    David G S Perahia
    Lilly Research Centre, Windlesham, Surrey, UK
    J Clin Psychiatry 69:95-105. 2008
  9. doi request reprint Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials
    Beth A Pangallo
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 26:2643-51. 2010
  10. ncbi request reprint Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics
    David G S Perahia
    Lilly Research Centre, Windlesham, Surrey, UK
    Int Clin Psychopharmacol 21:285-95. 2006

Detail Information

Publications11

  1. ncbi request reprint Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
    David G S Perahia
    Lilly Research Centre, Windlesham, Surrey, UK
    Int Clin Psychopharmacol 21:311-7. 2006
    ....
  2. doi request reprint Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER
    Catherine Reed
    Eli Lilly and Company Ltd, Erl Wood Manor, Windlesham, Surrey, UK
    J Affect Disord 113:296-302. 2009
    ..We studied the impact of antidepressant (AD) treatment on HRQoL outcomes in depressed patients and investigated factors associated with these outcomes in routine practice settings...
  3. doi request reprint Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression
    David G S Perahia
    Lilly Research Centre, EMC Building, Erl Wood Manor, Sunninghill Road, Windlesham GU20 6PH, Surrey, UK
    J Psychiatr Res 43:512-8. 2009
    ..In summary, MDD patients who were non- or partial-responders to SSRI treatment were found to have clinically significant pain which improved significantly following switch to duloxetine regardless of the switch method utilized...
  4. ncbi request reprint A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder
    David G S Perahia
    Lilly Research Centre, Erl Wood, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
    J Psychiatr Res 42:22-34. 2008
    ..The objective was to compare the serotonin and norepinephrine reuptake inhibitors (SNRIs) duloxetine and venlafaxine using GBR assessment...
  5. ncbi request reprint Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial
    David G S Perahia
    Lilly Research Centre, Erl Wood, Windlesham, Surrey, UK
    J Clin Psychiatry 70:706-16. 2009
    ..To assess the efficacy of duloxetine 60-120 mg once daily in the prevention of depressive recurrence in outpatients with recurrent major depressive disorder (MDD)...
  6. ncbi request reprint Factors influencing depression endpoints research (FINDER): study design and population characteristics
    Ana Garcia-Cebrian
    Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
    Eur Psychiatry 23:57-65. 2008
    ..Further investigation into factors associated with HRQoL in depression after treatment initiation is warranted...
  7. ncbi request reprint A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression
    David G S Perahia
    Lilly Research Centre, Windlesham, UK
    J Affect Disord 108:33-41. 2008
    ..We hypothesized that combining antidepressant medication with a standardized telephone adherence support intervention would lead to superior outcomes in the treatment of depression compared with antidepressant medication alone...
  8. ncbi request reprint Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques
    David G S Perahia
    Lilly Research Centre, Windlesham, Surrey, UK
    J Clin Psychiatry 69:95-105. 2008
    ..To compare 2 methods of switching selective serotonin reuptake inhibitor (SSRI) non-responders or partial responders to duloxetine...
  9. doi request reprint Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials
    Beth A Pangallo
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 26:2643-51. 2010
    ....
  10. ncbi request reprint Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics
    David G S Perahia
    Lilly Research Centre, Windlesham, Surrey, UK
    Int Clin Psychopharmacol 21:285-95. 2006
    ..Duloxetine was effective in the treatment of first and subsequent episodes of major depressive disorder, and regardless of duration of the current depressive episode...
  11. doi request reprint Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study
    Michael Bauer
    Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universitat Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Eur Psychiatry 23:66-73. 2008
    ..In conclusion, the prescribing of antidepressants varies by country, and the type of antidepressant chosen is influenced by physician- as well as patient-related factors...